McAndrews Secures TTAB Victory for Client AbbVie

McAndrews shareholders Patrick J. Arnold and Edward A. Mas II secured dismissal of an opposition proceeding in a trademark opposition before the Trademark Trial and Appeal Board (TTAB) for client AbbVie Biotechnology Ltd. 

01.28.19
Results | Design Rights, IP Transactions

McAndrews Wins $254M Damages Award in Stryker Corporation v. Zimmer, Inc.

McAndrews shareholders, Sharon Hwang, Deborah Laughton, and Stephanie Samz, have won an affirmance from the U.S. Court of Appeals for the Federal Circuit of a $254 million judgment for Stryker Corporation in one of the largest enhanced damage awards in patent history.

12.12.18
Results | IP Litigation, IP Transactions, Patent Prosecution, Post-Grant Practice

McAndrews Successfully Defends Netlist Memory Patents Against Six IPR Challenges

McAndrews announced today that the Federal Circuit has affirmed four decisions of the Patent Trial and Appeal Board (“PTAB”), in favor of its client, Netlist, Inc.

11.16.17
Results | IP Litigation, IP Transactions, Patent Prosecution, Post-Grant Practice

Supreme Court Sides with Stryker in Pivotal Patent Lawsuit over Enhanced Damages

The Supreme Court’s Stryker/Halo decision makes easier for Courts to award enhanced damages in patent infringement cases.

06.16.16
Results | IP Litigation, IP Transactions, Patent Prosecution, Post-Grant Practice

McAndrews Facilitated Divestiture of Stem Cell Business of Client Osiris Therapeutics for $100 Million

McAndrews guided client Osiris Therapeutics (NASDAQ:OSIR) in intellectual property matters involving
the sale of Osiris’s culture-expanded mesenchymal stem cell (ceMSC) business (including Osiris’ large
ceMSC patent estate) to Mesoblast International, SARL (ASX:MSB) (USOTC:MBLTY).

04.09.14
Results | IP Litigation, IP Transactions, Post-Grant Practice

"Our professional associations have been among the highlights of my 20-year career. I greatly appreciate having had the opportunity to work with you and your firm."

Chief Patent Counsel